{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:46Z","timestamp":1787019646060,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab, a humanized monoclonal antibody against the HER2 receptor is currently being used in breast and other tumor types. Early studies have shown that a variable proportion of cervical carcinoma tumors overexpress the HER2 receptor as evaluated by diverse techniques and antibodies. Currently it is known that a tumor response to trastuzumab strongly correlates with the level of HER2 expression evaluated by the Hercep Test, thus, it seems desirable to evaluate the status of expression of this receptor using the FDA-approved Hercep Test and grading system to gain insight in the feasibility of using trastuzumab in cervical cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed a series of cervical cancer cell lines, the primary tumors of 35 cases of cervical cancer patients and four recurrent cases, with the Hercep Test in order to establish whether this tumor type overexpress HER2 at level of 2+\/3+ as trastuzumab is currently approved for breast cancer having such level of expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results indicate that only 1 out of 35 primary tumors cases overexpress the receptor at this level, however, two out of four recurrent tumors that tested negative at diagnosis shifted to Hercep Test 2+ and 3+ respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The low frequency of expression in primary cases suggests that trastuzumab could have a limited value for the primary management of cervical cancer patients, however, the finding of \"conversion\" to Hercep Test 2+ and 3+ of recurrent tumors indicates the need to further evaluate the expression of HER2 in the metastatic and recurrent cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2407-4-59","type":"journal-article","created":{"date-parts":[[2004,9,7]],"date-time":"2004-09-07T02:23:56Z","timestamp":1094523836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["HER2 expression in cervical cancer as a potential therapeutic target"],"prefix":"10.1186","volume":"4","author":[{"given":"Alma","family":"Chavez-Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Perez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gonzalez-Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Vela-Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Candelaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucely","family":"Cetina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Due\u00f1as-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"149_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0305-7372(03)00068-9","volume":"29","author":"A Due\u00f1as-Gonzalez","year":"2003","unstructured":"Due\u00f1as-Gonzalez A, Cetina L, Mariscal I, de la Garza J: Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003, 29: 389-399. 10.1016\/S0305-7372(03)00068-9.","journal-title":"Cancer Treat Rev"},{"key":"149_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1006\/gyno.1998.5301","volume":"73","author":"JL Chang","year":"1999","unstructured":"Chang JL, Tsao YP, Liu DW, Han CP, Lee WH, Chen SL: The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. Gynecol Oncol. 1999, 73: 62-71. 10.1006\/gyno.1998.5301.","journal-title":"Gynecol Oncol"},{"key":"149_CR3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/107327480200900607","volume":"9","author":"J Horton","year":"2002","unstructured":"Horton J: Trastuzumab use in breast cancer: clinical issues. Cancer Control. 2002, 9: 499-507.","journal-title":"Cancer Control"},{"key":"149_CR4","first-page":"2771","volume":"54","author":"MF Press","year":"1994","unstructured":"Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2\/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994, 54: 2771-2777.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"149_CR5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/annonc\/12.suppl_1.S15","volume":"12","author":"S Menard","year":"2001","unstructured":"Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E: HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001, 12 (Suppl 1): S15-19. 10.1023\/A:1011151505425.","journal-title":"Ann Oncol"},{"key":"149_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K","volume":"78","author":"GB Kristensen","year":"1996","unstructured":"Kristensen GB, Holm R, Abeler VM, Trope CG: Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer. 1996, 78: 433-440. 10.1002\/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.3.CO;2-E.","journal-title":"Cancer"},{"key":"149_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/1097-0142(19940201)73:3<668::AID-CNCR2820730327>3.0.CO;2-D","volume":"73","author":"K Oka","year":"1994","unstructured":"Oka K, Nakano T, Arai T: c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer. 1994, 73: 664-671.","journal-title":"Cancer"},{"key":"149_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/1097-0142(19940101)73:1<148::AID-CNCR2820730125>3.0.CO;2-C","volume":"73","author":"T Kihana","year":"1994","unstructured":"Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, Matsuura S, Hirohashi S: Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Cancer. 1994, 73: 148-153.","journal-title":"Cancer"},{"key":"149_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1525-1438.2003.13397.x","volume":"13","author":"Y Niibe","year":"2003","unstructured":"Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H: Prognostic significance of c-erbB-2\/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer. 2003, 13: 849-855. 10.1111\/j.1525-1438.2003.13397.x.","journal-title":"Int J Gynecol Cancer"},{"key":"149_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1006\/gyno.2002.6648","volume":"85","author":"JS Lee","year":"2002","unstructured":"Lee JS, Kim HS, Jung JJ, Lee MC, Park CS: Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol. 2002, 85: 469-475. 10.1006\/gyno.2002.6648.","journal-title":"Gynecol Oncol"},{"key":"149_CR11","first-page":"1159","volume":"8","author":"TW Leung","year":"2001","unstructured":"Leung TW, Cheung AN, Cheng DK, Wong LC, Ngan HY: Expressions of c-erbB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep. 2001, 8: 1159-1164.","journal-title":"Oncol Rep"},{"key":"149_CR12","first-page":"493","volume":"44","author":"MG Hove","year":"1999","unstructured":"Hove MG, Dinh TV, Hannigan EV, Lucci JA, Chopra V, Smith ER, To T: Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib squamous cell carcinoma of the cervix. J Reprod Med. 1999, 44: 493-496.","journal-title":"J Reprod Med"},{"key":"149_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s004320050248","volume":"125","author":"T Nishioka","year":"1999","unstructured":"Nishioka T, West CM, Gupta N, Wilks DP, Hendry JH, Davidson SE, Hunter RD: Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol. 1999, 125: 96-100. 10.1007\/s004320050248.","journal-title":"J Cancer Res Clin Oncol"},{"key":"149_CR14","first-page":"577","volume":"5","author":"AM Kersemaekers","year":"1999","unstructured":"Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ: Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res. 1999, 5: 577-586.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"149_CR15","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/annonc\/12.suppl_1.S81","volume":"12","author":"S Scholl","year":"2001","unstructured":"Scholl S, Beuzeboc P, Pouillart P: Targeting HER2 in other tumor types. Ann Oncol. 2001, 12 (Suppl 1): S81-87. 10.1023\/A:1011192622688.","journal-title":"Ann Oncol"},{"key":"149_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003, 21: 283-290. 10.1200\/JCO.2003.10.104.","journal-title":"J Clin Oncol"},{"key":"149_CR17","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","volume":"39","author":"R Haddad","year":"2003","unstructured":"Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003, 39: 724-727. 10.1016\/S1368-8375(03)00097-6.","journal-title":"Oral Oncol"},{"key":"149_CR18","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","volume":"291","author":"H Yaziji","year":"2004","unstructured":"Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004, 291: 1972-1977. 10.1001\/jama.291.16.1972.","journal-title":"JAMA"},{"key":"149_CR19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1349-7006.2002.tb01231.x","volume":"93","author":"M Fujimura","year":"2002","unstructured":"Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki S, Hidaka T, Sakai M, Saito S: HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab. Jpn J Cancer Res. 2002, 93: 1250-1257.","journal-title":"Jpn J Cancer Res"},{"key":"149_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1525-1438.2003.13028.x","volume":"13","author":"H Iwamoto","year":"2003","unstructured":"Iwamoto H, Fukasawa H, Honda T, Hirata S, Hoshi K: HER2 expression in ovarian clear cell carcinomas. Int J Gynecol Cancer. 2003, 13: 28-31.","journal-title":"Int J Gynecol Cancer"},{"key":"149_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/sj.bjc.6600286","volume":"86","author":"FR Hirsch","year":"2002","unstructured":"Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA: Evaluation of HER2 gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002, 86: 1449-1456. 10.1038\/sj.bjc.6600286.","journal-title":"Br J Cancer"},{"key":"149_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ijc.11137","volume":"105","author":"DR Nathanson","year":"2003","unstructured":"Nathanson DR, Culliford AT, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F, Paty PB: HER 2\/neu expression and gene amplification in colon cancer. Int J Cancer. 2003, 105: 796-802. 10.1002\/ijc.11137.","journal-title":"Int J Cancer"},{"key":"149_CR23","first-page":"815","volume":"11","author":"S Matsuyama","year":"2004","unstructured":"Matsuyama S, Kitajima Y, Sumi K, Mori D, Satoh T, Miyazaki K: Gallbladder cancers rarely overexpress HER2, demonstrated by Hercep Test. Oncol Rep. 2004, 11: 815-819.","journal-title":"Oncol Rep"},{"issue":"5A","key":"149_CR24","first-page":"4067","volume":"23","author":"A Potti","year":"2003","unstructured":"Potti A, Hille R, Koch M: Immunohistochemical determination of HER2 in malignant melanoma. Anticancer Res. 2003, 23 (5A): 4067-4069.","journal-title":"Anticancer Res"},{"key":"149_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0090-8258(03)00460-8","volume":"91","author":"S Bellone","year":"2003","unstructured":"Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD: Selection of HER2-positive tumor cells in early stage cervical cancer: implications for Trastuzumab-mediated therapy. Gynecol Oncol. 2003, 91: 231-240. 10.1016\/S0090-8258(03)00460-8.","journal-title":"Gynecol Oncol"},{"key":"149_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20: 719-726. 10.1200\/JCO.20.3.719.","journal-title":"J Clin Oncol"},{"key":"149_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdh031","volume":"15","author":"U Gatzemeier","year":"2004","unstructured":"Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004, 15: 19-27. 10.1093\/annonc\/mdh031.","journal-title":"Ann Oncol"},{"key":"149_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdf252","volume":"13","author":"D Gancberg","year":"2002","unstructured":"Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002, 13: 1036-1043. 10.1093\/annonc\/mdf252.","journal-title":"Ann Oncol"},{"key":"149_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1023\/A:1014730829872","volume":"6","author":"SA Eccles","year":"2001","unstructured":"Eccles SA: The role of c-erbB-2\/HER2\/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2001, 6: 393-406. 10.1023\/A:1014730829872.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"149_CR30","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1038\/sj.onc.1206394","volume":"22","author":"C Knuefermann","year":"2003","unstructured":"Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z: HER2\/PI-3K\/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003, 22: 3205-3212. 10.1038\/sj.onc.1206394.","journal-title":"Oncogene"},{"issue":"3 Pt 1","key":"149_CR31","first-page":"381","volume":"76","author":"A Berchuck","year":"1990","unstructured":"Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC: Expression of epidermal growth factor receptor and HER2 in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990, 76 (3 Pt 1): 381-387.","journal-title":"Obstet Gynecol"},{"key":"149_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/gte.1999.3.237","volume":"3","author":"HF Mark","year":"1999","unstructured":"Mark HF, Feldman D, Das S, Sun CL, Samy M, Lathrop J: HER-2\/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. Genet Test. 1999, 3: 237-242.","journal-title":"Genet Test"},{"key":"149_CR33","first-page":"2985","volume":"9","author":"A Dellas","year":"2003","unstructured":"Dellas A, Torhorst J, Gaudenz R, Mihatsch MJ, Moch H: DNA copy number changes in cervical adenocarcinoma. Clin Cancer Res. 2003, 9: 2985-2991.","journal-title":"Clin Cancer Res"},{"key":"149_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF00694752","volume":"35","author":"HS Earp","year":"1995","unstructured":"Earp HS, Dawson TL, Li X, Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995, 35: 115-32.","journal-title":"Breast Cancer Res Treat"},{"key":"149_CR35","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/S0046-8177(03)00409-X","volume":"34","author":"L Hammock","year":"2003","unstructured":"Hammock L, Lewis M, Phillips C, Cohen C: Strong HER-2\/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol. 2003, 34: 1043-1047. 10.1053\/S0046-8177(03)00409-X.","journal-title":"Hum Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-59.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-4-59\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-59","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-59.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:35:48Z","timestamp":1728290148000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-4-59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-4-59","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,1]]},"assertion":[{"value":"14 April 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"59"}}